

## **ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen 32nd Annual Health Care Conference**

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the Cowen 32<sup>nd</sup> Annual Health Care Conference at 10:40 am ET on March 7, 2012 will be webcast live.

The webcast of this presentation can be accessed live through the "Investor Information" section of the Company's website, [www.immunogen.com](http://www.immunogen.com); a replay of the presentation will be available at the same location for one week.

### **About ImmunoGen, Inc.**

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at [www.immunogen.com](http://www.immunogen.com).

For Investors:

ImmunoGen, Inc.

Carol Hausner, 781-895-0600

Executive Director, Investor Relations  
and Corporate Communications

[info@immunogen.com](mailto:info@immunogen.com)

or

For Media:

The Yates Network

Barbara Yates, 781-258-6153

Source: ImmunoGen, Inc.

News Provided by Acquire Media